BR112021019066A2 - Receptores de células t para mage a4 - Google Patents

Receptores de células t para mage a4

Info

Publication number
BR112021019066A2
BR112021019066A2 BR112021019066A BR112021019066A BR112021019066A2 BR 112021019066 A2 BR112021019066 A2 BR 112021019066A2 BR 112021019066 A BR112021019066 A BR 112021019066A BR 112021019066 A BR112021019066 A BR 112021019066A BR 112021019066 A2 BR112021019066 A2 BR 112021019066A2
Authority
BR
Brazil
Prior art keywords
tcr
mage
cell receptors
relates
cell
Prior art date
Application number
BR112021019066A
Other languages
English (en)
Inventor
Christian Ellinger
Daniel Sommermeyer
Blackburn Parsons Geoffrey
Jasdeep Mann
Original Assignee
2Seventy Bio Inc
Medigene Immunotherapies Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 2Seventy Bio Inc, Medigene Immunotherapies Gmbh filed Critical 2Seventy Bio Inc
Publication of BR112021019066A2 publication Critical patent/BR112021019066A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Developmental Biology & Embryology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

receptores de células t para mage a4. a presente invenção refere-se a um receptor de células t (tcr) isolado, específico para o mage-a4, e um polipeptídeo compreendendo uma parte funcional do tcr. ainda estão implicados um complexo de tcr multivalente, um ácido nucleico que codifica um tcr, uma célula que expressa o tcr e uma composição farmacêutica que compreende o tcr. a invenção também se refere ao tcr para uso como medicamento, em particular ao tcr para uso no tratamento do câncer.
BR112021019066A 2019-03-27 2020-03-27 Receptores de células t para mage a4 BR112021019066A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19165387.2A EP3714941A1 (en) 2019-03-27 2019-03-27 Mage-a4 tcrs
PCT/EP2020/058779 WO2020193767A1 (en) 2019-03-27 2020-03-27 Mage a4 t cell receptors

Publications (1)

Publication Number Publication Date
BR112021019066A2 true BR112021019066A2 (pt) 2021-11-30

Family

ID=66000958

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021019066A BR112021019066A2 (pt) 2019-03-27 2020-03-27 Receptores de células t para mage a4

Country Status (15)

Country Link
US (1) US20230159612A1 (pt)
EP (2) EP3714941A1 (pt)
JP (1) JP2022527635A (pt)
KR (1) KR20210150440A (pt)
CN (1) CN114126716B (pt)
AU (1) AU2020249598A1 (pt)
BR (1) BR112021019066A2 (pt)
CA (1) CA3134076A1 (pt)
CL (1) CL2021002491A1 (pt)
CO (1) CO2021012587A2 (pt)
EA (1) EA202192327A1 (pt)
IL (1) IL286569A (pt)
MX (1) MX2021011613A (pt)
SG (1) SG11202110171QA (pt)
WO (1) WO2020193767A1 (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114375301A (zh) * 2019-05-08 2022-04-19 基因医疗免疫疗法有限责任公司 工程改造的t细胞
AU2021244594A1 (en) * 2020-03-27 2022-12-01 Regeneron Pharmaceuticals, Inc. T cell receptors
CN111647069B (zh) * 2020-06-17 2022-06-21 深圳豪石生物科技有限公司 一种改进的tcr及其应用
MX2023010541A (es) 2021-03-09 2023-11-24 Cdr Life Ag Proteinas de union al antigeno del peptido del mhc mage-a4.
CN115975003B (zh) * 2021-03-09 2024-01-26 科士华(南京)生物技术有限公司 Tcr、多肽、表达载体、宿主细胞、药物组合物和tcr获得方法
EP4091627A1 (en) 2021-05-21 2022-11-23 Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft Tcr constructs specific for magea4-derived epitopes
KR20240034234A (ko) 2021-07-14 2024-03-13 2세븐티 바이오, 인코포레이티드 항체로부터의 결합 도메인에 융합된 조작된 t 세포 수용체
CN116836261A (zh) * 2022-03-24 2023-10-03 香雪生命科学技术（广东）有限公司 一种识别mage-a4抗原的高亲和力tcr及其序列和应用
WO2023196997A2 (en) 2022-04-08 2023-10-12 2Seventy Bio, Inc. Multipartite receptor and signaling complexes
WO2023230512A1 (en) 2022-05-26 2023-11-30 2Seventy Bio, Inc. Compositions for maintaining lentiviral vector and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4703004A (en) 1984-01-24 1987-10-27 Immunex Corporation Synthesis of protein with an identification peptide
US4851341A (en) 1986-12-19 1989-07-25 Immunex Corporation Immunoaffinity purification system
ES2239246T3 (es) 2001-08-31 2005-09-16 Avidex Limited Receptor soluble de celulas t.
EP2006376A1 (en) 2007-06-21 2008-12-24 Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt GmbH Fusion protein comprising a caspase domain and a nuclear hormone receptor binding domain and methods and uses thereof
ES2925307T3 (es) * 2012-09-14 2022-10-14 Us Health Receptores de linfocitos T que reconocen MAGE-A3 restringida al MHC de clase II
HRP20211493T1 (hr) * 2016-04-08 2022-01-21 Adaptimmune Limited Receptori t stanica
KR102473964B1 (ko) * 2016-04-08 2022-12-06 이뮤노코어 리미티드 T 세포 수용체
SG11202001368SA (en) * 2017-08-18 2020-03-30 Gritstone Oncology Inc Antigen-binding proteins tatrgeting shared antigens

Also Published As

Publication number Publication date
KR20210150440A (ko) 2021-12-10
CN114126716A (zh) 2022-03-01
WO2020193767A1 (en) 2020-10-01
CO2021012587A2 (es) 2022-02-28
IL286569A (en) 2021-12-01
CA3134076A1 (en) 2020-10-01
MX2021011613A (es) 2021-12-15
US20230159612A1 (en) 2023-05-25
CL2021002491A1 (es) 2022-06-10
EP3714941A1 (en) 2020-09-30
JP2022527635A (ja) 2022-06-02
EP3946621A1 (en) 2022-02-09
CN114126716B (zh) 2024-05-24
SG11202110171QA (en) 2021-10-28
EA202192327A1 (ru) 2022-01-19
AU2020249598A1 (en) 2021-10-28

Similar Documents

Publication Publication Date Title
BR112021019066A2 (pt) Receptores de células t para mage a4
EA202092032A1 (ru) Т-клеточный рецептор, специфичный в отношении ny-eso-1/lage-1, и его применения
PH12021550307A1 (en) T Cell Receptor Constructs And Uses Thereof
BR112016013187A2 (pt) receptores de antígenos quiméricos de mesotelina humanos e usos dos mesmos
EA201991696A1 (ru) Т-клеточные рецепторы, связывающиеся с ny-eso-1, и способы их применения
CR20180422A (es) PÉPTIDOS Y COMBINACIÓN DE PÉPTIDOS NOVEDOSOS PARA SU USO EN INMUNOTERAPIA CONTRA DIVERSOS TUMORES (DIivisional 2017-0522)
CL2021002997A1 (es) Construcción de reconocimiento de antígeno y su uso para el tratamiento de enfermedades proliferativas y para la detección in vitro de un cáncer (divisional de la solicitud 201901535)
MX2015003061A (es) Receptores de la celula t que reconocen mhc de mage-a3 de calse ii-restringida.
BR112016027805A2 (pt) receptores de células t do anti-papilomavírus humano 16 e7
BR112019018863A8 (pt) Tcrs de alta afinidade específicos para mage-a1 e usos dos mesmos
BR112019011065A2 (pt) métodos para determinação da dosagem de células t car
BR112015019985A2 (pt) Novo análogo de insulina e sua utilização
EP3656387A3 (en) Genetically modified mesenchymal stem cells expressing an immune response-stimulating cytokine to attract and/or activate immune cells
BR112018003535A2 (pt) receptor de antígeno quimérico, vetor de expressão, composição farmacêutica, e, uso de um vetor de expressão
MA49355A (fr) Formats de récepteurs de liaison d'antigène améliorés
BR112013018399A2 (pt) anticorpos anti-il1rap e seus usos para tratamento humano
BR112017001242A2 (pt) tratamento de câncer usando um receptor antigênico quimérico a cd33
CL2012001539A1 (es) Anticuerpo 005-c04 que antagonizan la señalizacion mediada por el receptor de prolactina; secuencia de acido nucleico que codifica dicho anticuerpo; vector de expresion y célula huesped que comprenden dicha secuencia de acido nucleico; uso del anticuerpo para terapia hormonal combinada; composicion farmacéutica que comprende el anticuerpo.
BR112013003647A2 (pt) receptores de células t.
AR095374A1 (es) Moléculas de unión para bcma y cd3
BR112015019603A2 (pt) Moléculas de ácido nucleico isoladas, molécula de polipeptídeo isolada, molécula isolada de car, domínio de ligação anti-egfrviii, vetor, célula e uso de uma quantidade eficaz da mesma e métodos para produção de uma célula e para a produção de uma população de células modificadas por rna
CO2019011018A2 (es) Ensayo para medir la potencia de las interaccioned del receptor-ligando en nanomedicinas
BR112016001036A2 (pt) fusocinas envolvendo citocinas com afinidades de ligação de receptores fortemente reduzida
BR112018006006A2 (pt) receptores de antígeno, cadeias peptídicas, células recombinantes, métodos para produzir uma célula que expressa um receptor de antígeno e para o tratamento de uma doença, ácidos nucleicos e composição farmacêutica
CL2009000862A1 (es) Anticuerpo aislado, derivados o fragmentos aislados del mismo capaz de unirse a la proteina cd151, composición que lo comprende; ácido nucleico que lo codifica, vector y célula huesped que lo comprenden; procedimiento para preparar dicho anticuerpo; util como medicamento para prevenir o tratar el cáncer.